Healthcare

Oracle and AstraZeneca partner on AI-enabled healthcare innovation

Oracle and AstraZeneca agreed to explore AI-enabled clinical-trial recruitment and evidence generation, with an initial hypertension-focused program in Abu Dhabi.

AstraZeneca and Oracle announced a collaboration to explore how artificial intelligence and real-world health data can help clinicians identify eligible patients for clinical trials and accelerate evidence generation. Oracle will contribute health-data, cloud, analytics, AI, and clinical-workflow capabilities, while AstraZeneca will provide scientific, therapeutic, clinical-development, and regulatory expertise. The initial Abu Dhabi program, conducted with M42, will focus on patients whose hypertension is not adequately controlled. Care teams will seek to identify those patients, support treatment according to clinical guidelines, and improve their access to relevant research studies. The companies said future projects may address oncology, cardiovascular, renal and metabolic disease, respiratory and immunological conditions, and rare diseases. The announcement is significant for healthcare automation because it connects patient records and clinical workflows with research processes, potentially reducing manual screening and helping trials reach suitable participants more efficiently. The agreement is non-binding and represents an exploration of use cases rather than a completed clinical deployment.

Original source: Oracle

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI